MUNDIPHARMA INTERNATIONAL (BERMUDA) LIMITED
Get an alert when MUNDIPHARMA INTERNATIONAL (BERMUDA) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£13M
+112.9% vs 2023
Net assets
£27M
+70.8% vs 2023
Employees
—
Average over period
Profit before tax
£53M
+189.1% vs 2023
Net assets
2-year trend · vs Unclassified median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £14,884,359 | £11,120,089 | |
| Operating profit | £8,541,883 | £3,549,296 | |
| Profit before tax | £18,176,427 | £52,540,400 | |
| Net profit | £16,801,334 | £40,994,070 | |
| Cash | £6,307,635 | £13,428,466 | |
| Total assets less current liabilities | — | — | |
| Net assets | £15,765,752 | £26,934,025 | |
| Equity | £15,765,752 | £26,934,025 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 57.4% | 31.9% | |
| Net margin | 112.9% | 368.6% | |
| Gearing (liabilities / total assets) | 43.3% | 14.3% | |
| Current ratio | 1.97x | 6.71x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- US GAAP
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young Ltd.
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
Significant events
- “On June 28, 2023, the Company entered an Asset Purchase Agreement for the sale of its rights in dihydrocodeine ("DHC") to Ennogen Healthcare International Limited ("Ennogen") for $4,673,000.”
- “On July 12, 2023, the Company entered an Asset Purchase Agreement for the sale of its rights in LTS's buprenorphine transdermal patch technology for the territory of Argentina to Biosidus S.A.U. ("Biosidus") for $1,150,000.”
- “On December 31, 2023, the Company agreed to a transaction to sell their Consumer Health businesses in Australia to iNova Pharmaceuticals (Singapore) Pte Limited ("iNova").”
- “On January 31, 2024, the Company sold their remaining Consumer Health business to iNova, receiving consideration of $65,504,000 and recorded a gain on disposal of intangible assets of $63,341,000.”
- “On June 28, 2024, the Company entered a License and Commericalization Agreement, transferring rights in morphine sulfate pentahydrate (Sevredol®) in New Zealand to Douglas Pharmaceuticals Limited ("Douglas") for $456,000 (NZD750,000).”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 0 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| OCORIAN SERVICES (BERMUDA) LIMITED | Corporate Secretary | 2021-07-14 | — | — |
| JAMIESON, Stephen Johan | Director | 2021-01-01 | Sep 1957 | British |
| LEA, Bryan George | Director | 2021-07-14 | Jun 1961 | British |
Ownership
Persons with significant control
Filing timeline
Last 10 of 10 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-24 | AA | accounts | Accounts with accounts type full | |
| 2025-02-26 | OSCH01 | other | Change company details by uk establishment overseas company with change details | |
| 2025-01-15 | AA | accounts | Accounts with accounts type full | |
| 2024-02-12 | AA | accounts | Accounts with accounts type full | |
| 2023-03-13 | AA | accounts | Accounts with accounts type full | |
| 2023-01-18 | OSAP01 | officers | Appoint person director overseas company with name appointment date | |
| 2022-04-13 | AA01 | accounts | Change account reference date company previous shortened | |
| 2021-07-14 | OS-PAR | annual-return | Appointment at registration of person authorised to represent | |
| 2021-07-14 | OS-PAR | annual-return | Appointment at registration of person authorised to accept service | |
| 2021-07-14 | OSIN01 | incorporation | Register overseas company |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 1
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-25.3%
£14,884,359 £11,120,089
-
Cash
+112.9%
£6,307,635 £13,428,466
-
Net assets
+70.8%
£15,765,752 £26,934,025
-
Employees
—
Not reported
-
Operating profit
-58.4%
£8,541,883 £3,549,296
-
Profit before tax
+189.1%
£18,176,427 £52,540,400
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers